Soluble CD40 ligand in dementia

Drugs of the Future

Volumn 34, Issue 4, 2009, Pages 333-339

  Giunta, B ^a   Figueroa, K P ^b   Town, T ^b,c   Tan, J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; ANTIRETROVIRUS AGENT; ATORVASTATIN; BIOLOGICAL MARKER; CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MEVINOLIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ASTROCYTE; BRAIN FUNCTION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE PRODUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED DEMENTIA; IMMUNOCOMPETENT CELL; MICROGLIA; MULTIINFARCT DEMENTIA; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 70849102410     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.04.1358595     Document Type: Review

References (99)

1. Brookmeyer, R., Gray, S., Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88(9): 1337-42.
2. Alzheimer's Association: 2009 Alzheimer's Disease Facts and Figures. www.alz.org/alzheimers-disease-facts-figures.asp.
3. Burns, A., Iliffe, S. Dementia. BMJ 2009, 338: b75.
4. Ghafouri, M., Amini, S., Khalili, K., Sawaya, B.E. HIV-1 associated dementia: Symptoms and causes. Retrovirology 2006, 3: 28.
5. Ponomarev, E.D., Shriver, L.P., Dittel, B.N. CD40 expression by microglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation. J Immunol 2006, 176(3): 1402-10.
6. Aloisi, F., De Simone, R., Columba-Cabezas, S., Penna, G., Adorini, L. Functional maturation of adult mouse resting microglia into an APC is promoted by granulocyte-macrophage colony-stimulating factor and interaction with Th1 cells. J Immunol 2000, 164(4): 1705-12.
7. D'Aversa, T.G., Weidenheim, K.M., Berman, J.W. CD40-CD40L interactions induce chemokine expression by human microglia: Implications for human immunodeficiency virus encephalitis and multiple sclerosis. Am J Pathol 2002, 160(2): 559-67.
8. Kawahara, K., Yoshida, A., Koga, K. et al. Marked induction of inducible nitric oxide synthase and tumor necrosis factor-alpha in rat CD40+ microglia by comparison to CD40- microglia. J Neuroimmunol 2009, 208(1-2): 70-9.
9. Townsend, K.P., Shytle, D.R., Bai, Y. et al. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J Neurosci Res 2004, 78(2): 167-76.
10. Chakrabarti, S., Rizvi, M., Pathak, D., Kirber, M.T., Freedman, J.E. Hypoxia influences CD40-CD40L mediated inflammation in endothelial and monocytic cells. Immunol Lett 2009, 122(2): 170-84.
11. Dubois, B., Vanbervliet, B., Fayette, J. et al. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J Exp Med 1997, 185(5): 941-51.
12. Abdel-Haq, N., Hao, H.N., Lyman, W.D. Cytokine regulation of CD40 expression in fetal human astrocyte cultures. J Neuroimmunol 1999, 101(1): 7-14.
13. Mach, F., Schonbeck, U., Sukhova, G.K. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997, 94(5): 1931-6.
14. Kim, K.M., Min, H.Y., Jung, S.H., Lee, T.H., Kim, J.G., Kang, C.Y. Characterization of an immunosuppressive anti-CD40 ligand monoclonal antibody. Hybridoma 1998, 17(5): 463-70.
15. D'Aversa, T.G., Eugenin, E.A., Berman, J.W. NeuroAIDS: Contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. J Neurosci Res 2005, 81(3): 436-46.
16. D'Aversa, T.G., Eugenin, E.A., Berman, J.W. CD40-CD40 ligand interactions in human microglia induce CXCL8 (interleukin-8) secretion by a mechanism dependent on activation of ERK1/2 and nuclear translocation of nuclear factor-kappaB (NFkappaB) and activator protein-1 (AP-1). J Neurosci Res 2008, 86(3): 630-9.
17. Calingasan, N.Y., Erdely, H.A., Altar, C.A. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging 2002, 23(1): 31-9.
18. Obradovic, S.D., Antovic, J.P., Antonijevic, N.M. et al. Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention. Blood Coagul Fibrinolysis 2009, Epub ahead of print.
19. Lessiani, G., Dragani, A., Falco, A., Fioritoni, F., Santilli, F., Davi, G. Soluble CD40 ligand and endothelial dysfunction in aspirin-treated polycythaemia vera patients. Br J Haematol 2009, Epub ahead of print.
20. Andre, P., Nannizzi-Alaimo, L., Prasad, S.K., Phillips, D.R. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease. Circulation 2002, 106(8): 896-9.
21. Perry, E.K., Perry, R.H. Neurochemistry of consciousness: Cholinergic pathologies in the human brain. Prog Brain Res 2004, 145: 287-99.
22. Johnson, K.A., Albert, M.S. Perfusion abnormalities in prodromal AD. Neurobiol Aging 2000, 21(2): 289-92.
23. Türker, S., Güneri, S., Akdeniz, B. et al. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol 2006, 97(2): 198-202.
24. Henn, V., Slupsky, J.R., Grafe, M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391(6667): 591-4.
25. Benveniste, E.N., Nguyen, V.T., Wesemann, D.R. Molecular regulation of CD40 gene expression in macrophages and microglia. Brain Behav Immun 2004, 18(1): 7-12.
26. Mukundan, L., Bishop, G.A., Head, K.Z., Zhang, L., Wahl, L.M., Suttles, J. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. J Immunol 2005, 174(2): 1081-90.
27. Urbich, C., Dernbach, E., Aicher, A., Zeiher, A.M., Dimmeler, S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002, 106(8): 981-6.
28. Kaul, M., Lipton, S.A. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 2006, 4(3): 307-18.
29. Avison, M.J., Nath, A., Greene-Avison, R. et al. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol 2004, 10(4): 223-32.
30. Bolokadze, N., Gabunia, P., Ezugbaia, M., Gatserelia, L., Khechiashvili, G. Neurological complications in patients with HIV/AIDS. Georgian Med News 2008, (165): 34-8.
31. Huang, Y., Erdmann, N., Peng, H., Zhao, Y., Zheng, J. The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases. Cell Mol Immunol 2005, 2(2): 113-22.
32. Gray, F., Bazille, C., Adle-Biassette, H., Mikol, J., Moulignier, A., Scaravilli, F. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005, 11(Suppl. 3): 16-22.
33. Lambotte, O., Deiva, K., Tardieu, M. HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol 2003, 13(1): 95-103.
34. McArthur, J.C., McDermott, M.P., McClernon, D. et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004, 61(11): 1687-96.
35. Fischer-Smith, T., Rappaport, J. Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev Mol Med 2005, 7(27): 1-26.
36. Rumbaugh, J.A., Nath, A. Developments in HIV neuropathogenesis. Curr Pharm Des 2006, 12(9): 1023-44.
37. Et-Hage, N., Bruce-Keller, A.J., Knapp, P.E., Hauser, K.F. CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice. J Neuroimmune Pharmacol 2008, 3(4): 275-85.
38. Sui, Z., Sniderhan, L.F., Schifitto, G., Phipps, R.P. et al. Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: Implications in HIV type 1 dementia. J Immunol 2007, 178(5): 3226-36.
39. Sawada, M. Neuroprotective and toxic changes in microglia in neurodegenerative disease. Parkinsonism Relat Disord 2009, 15(Suppl. 1): S39-41.
40. Sipsas, N.V., Sfikakis, P.P., Kontos, A., Kordossis, T. Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4(+) T-cell counts. Clin Diagn Lab Immunol 2002, 9(3): 558-61.
41. Eugenin, E.A., Osiecki, K., Lopez, L., Goldstein, H., Calderon, T.M., Berman, J.W. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: A potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 2006, 26(4): 1098-106.
42. de Gaetano Donati, K., Rabagliati, R., Iacoviello, L., Cauda, R. HIV infection, HAART, and endothelial adhesion molecules: Current perspectives. Lancet Infect Dis 2004, 4(4): 213-22.
43. van Vonderen, M.G., Hassink, E.A., van Agtmael, M.A. et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009, 199(8): 1186-94.
44. Wolf, K., Tsakiris, D.A., Weber, R., Erb, P., Battegay, M. Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human Immunodeficiency virus type 1. J Infect Dis 2002, 185(4): 456-62.
45. Sallem, W., Serradji, N., Dereuddre-Bosquet, N., Dive, G., Clayette, P., Heymans, F. Structure-activity relationships in platelet-activating factor. Part 14: Synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity. Bioorg Med Chem 2006, 14(23): 7999-8013.
46. Aukrust, P., Bjornsen, S., Lunden, B. et al. Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Thromb Haemost 2000, 84(2): 183-7.
47. de Larranaga, G.F., Bocassi, A.R., Puga, L.M., Alonso, B.S., Benetucci, J.A. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 2003, 110(2-3): 93-8.
48. Khovidhunkit, W., Memon, R.A., Shigenaga, J.K. et al. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999, 48(12): 1524-31.
49. Yoshimura, T., Matsushima, K., Oppenheim, J.J., Leonard, E.J. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: Partial characterization and separation from interleukin 1 (IL 1). J Immunol 2005, 175(9): 5569-74.
50. Baggiolini, M., Walz, A., Kunkel, S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989, 84(4): 1045-9.
51. Leonard, E.J., Skeel, A., Yoshimura, T., Noer, K., Kutvirt, S., Van Epps, D. Leukocyte specificity and binding of human neutrophil attractant/activation protein-1. J Immunol 1990, 144(4): 1323-30.
52. Gerszten, R.E., Garcia-Zepeda, E.A., Lim, Y.C. et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999, 398(6729): 718-23.
53. Sanders, V.J., Pittman, C.A., White, M.G., Wang, G., Wiley, C.A., Achim, C.L. Chemokines and receptors in HN encephalitis. AIDS 1998, 12(9): 1021-6.
54. Xiong, H., Boyle, J., Winkelbauer, M. et al. Inhibition of long-term potentiation by interleukin-8: Implications for human immunodeficiency virus-1-associated dementia. J Neurosci Res 2003, 71(4): 600-7.
55. Zheng, J.C., Huang, Y., Tang, K. et al. HIV-1-infected and/or immune-activated macrophages regulate astrocyte CXCL8 production through IL-1β and TNF-α: Involvement of mitogen-activated protein kinases and protein kinase R. J Neuroimmunol 2008, 200(1-2): 100-10.
56. Lane, B.R., Lore, K., Bock, P.J. et al. Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. J Virol 2001, 75(17): 8195-202.
57. Selkoe, D.J. Developing preventive therapies for chronic diseases: Lessons learned from Alzheimer's disease. Nutr Rev 2007, 65(12, Pt. 2): S239-43.
58. Selkoe, D.J. Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 2001, 81(2): 741-66.
59. Kalaria, R.N. Cerebral vessels in ageing and Alzheimer's disease. Pharmacol Ther 1996, 72(3): 193-214.
60. Akiyama, H., Barger, S., Barnum, S. et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21(3): 383-421.
61. Meda, L., Cassatella, M.A., Szendrei, G.I. et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374(6523): 647-50.
62. Tan, J., Town, T., Paris, D. et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999, 286(5448): 2352-5.
63. Tan, J., Town, T., Suo, Z. et al. Induction of CD40 on human endothelial cells by Alzheimer's beta-amyloid peptides. Brain Res Bull 1999, 50(2): 143-8.
64. Togo, T., Akiyama, H., Kondo, H. et al. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res 2000, 885(1): 117-21.
65. Desideri, G., Cipollone, F., Necozione, S. et al. Enhanced soluble CD40 ligand and Alzheimer's disease: Evidence of a possible pathogenetic role. Neurobiol Aging 2008, 29(3): 348-56.
66. Tousoulis, D., Antoniades, C., Nikolopoulou, A. et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest 2007, 37(8): 623-8.
67. Vermeer, S.E., Hollander, M., van Dijk, E.J. et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: The Rotterdam Scan Study. Stroke 2003, 34(5): 1126-9.
68. Suo, Z., Tan, J., Placzek, A., Crawford, F., Fang, C., Mullan, M. Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: The roles of cytokines and CD40. Brain Res 1998, 807(1-2): 110-7.
69. Breteler, M.M. Vascular risk factors for Alzheimer's disease: An epidemiologic perspective. Neurobiol Aging 2000, 21(2): 153-60.
70. de la Torre, J.C. Critically attained threshold of cerebral hypoperfusion: The CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 2000, 21(2): 331-42.
71. Snowdon, D.A., Greiner, L.H., Mortimer, J.A., Riley, K.P., Greiner, P.A., Markesbery, W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997, 277(10): 813-7.
72. Kalaria, R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000, 21(2): 321-30.
73. Sevush, S., Jy, W., Horstman, L.L., Mao, W.W., Kolodny, L., Ahn, Y.S. Platelet activation in Alzheimer disease. Arch Neurol 1998, 55(4): 530-6.
74. Town, T., Tan, J., Mullan, M. CD40 signaling and Alzheimer's disease pathogenesis. Neurochem Int 2001, 39(5-6): 371-80.
75. Tan, J., Town, T., Mullan, M. CD40-CD40L interaction in Alzheimer's disease. Curr Opin Pharmacol 2002, 2(4): 445-51.
76. Town, T., Tan, J., Flavell, R.A., Mullan, M. T-cells in Alzheimer's disease. Neuromol Med 2005, 7(3): 255-64.
77. Greenwood, J., Wang, Y., Calder, V.L. Lymphocyte adhesion and transendothelial migration in the central nervous system: The role of LFA-1, ICAM-1, VLA-4 and VCAM-1. Immunology 1995, 86(3): 408-15.
78. Saito, M., Ota, Y., Ohashi, H. et al. CD40-CD40 ligand signal induces the intercellular adhesion molecule-1 expression through nuclear factor-kappa B p50 in cultured salivary gland epithelial cells from patients with Sjögren's syndrome. Mod Rheumatol 2007, 17(1): 45-53.
79. Mandrekar, S., Jiang, Q., Lee, C.Y., Koenigsknecht-Talboo, J., Holtzman, D.M., Landreth, G.E. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci 2009, 29(13): 4252-62.
80. Tan, J., Town, T., Paris, D. et al. Activation of microglial cells by the CD40 pathway: Relevance to multiple sclerosis. J Neuroimmunol 1999, 97(1-2): 77-85.
81. Ait-Ghezala, G., Mathura, V.S., Laporte, V. et al. Genomic regulation after CD40 stimulation in microglia: Relevance to Alzheimer's disease. Mol Brain Res 2005, 140(1-2): 73-85.
82. Laporte, V., Ait-Ghezala, G., Volmar, C.H., Mullan, M. CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. J Neuroinflammation 2006, 3: 3.
83. Todd Roach, J., Volmar, C.H., Dwivedi, S. et al. Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice. Brain Res 2004, 1015(1-2): 161-8.
84. Tarkowski, E., Liljeroth, A.M., Minthon, L., Tarkowski A., Wallin, A., Blennow, K., Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 2003, 61(3): 255-60.
85. Ray, S., Britschgi, M., Herbert, C. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13(11): 1359-62.
86. Cramer, C., Haan, M.N., Galea, S., Langa, K.M., Kalbfleisch, J.D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008, 71(5): 344-50.
87. Townsend, K.P., Shytle, D.R., Bai, Y. et al. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J Neurosci Res 2004, 78(2): 167-76.
88. Sparks, D.L., Sabbagh, M.N., Connor, D.J. et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch Neurol 2005, 62(5): 753-7.
89. Sparks, D.L., Kryscio, R.J., Sabbagh, M.N., Connor, D.J., Sparks, L.M., Liebsack, C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008, 5(4): 416-21.
90. Jones, R.W., Kivipelto, M., Feldman, H. et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. Alzheimers Dement 2008, 4(2): 145-53.
91. Santini, E., Madec, S., Corretti, V., Ferrannini, E., Solini, A. Effect of statins on soluble CD40 ligand in hypercholesterolemic type 2 diabetic patients. J Endocrinol Invest 2008, 31(7): 660-5.
92. Blanco-Colio, L.M., Martin-Ventura, J.L., de Teresa E. et al. Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: A substudy of ACTFAST. Kidney Int Suppl 2008, (111): S60-3.
93. Haag, M.D., Hofman, A., Koudstaal, P.J., Stricker, B.H., Breteler, M.M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009, 80(1): 13-7.
94. Nikolic, W.V., Hou, H., Town, T. et al. Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev 2008, 17(3): 423-39.
95. Schenk, D., Barbour, R., Dunn, W. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(6740): 173-7.
96. Morgan, D., Diamond, D.M., Gottschall, P.E. et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408(6815): 982-5.
97. Janus, C., Pearson, J., McLaurin, J. et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408(6815): 979-82.
98. Hock, C., Konietzko, U., Streffer, J.R. et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38(4): 547-54.
99. Obregon, D., Hou, H., Bai, Y. et al. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. Neurobiol Dis 2008, 29(2): 336-53.